Key Takeaways
- Immunovant’s CEO is retiring and will be replaced by a Roivant insider, firming up the parent company’s oversight on its subsidiary as Immunovant focuses on execution of its IMVT-1402 development plan.
- Two new indications were announced for IMVT-1402 – cutaneous lupus erythematosus and Sjögren’s disease – but the total potential initial indications were cut from 10 to six.
- Analysts foresaw positives in the strategic updates, but investors were slightly negative about the leadership shakeup and narrowing of indication focus for IMVT-1402.
Roivant’s confidence in Immunovant’s neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402 has only grown, Roivant CEO Matt Gline said, since the company and its subsidiary announced earlier this year that the asset’s development would be prioritized over pursuing approval of Immunovant’s later-stage anti-FcRn antibody
Immunovant CEO Pete Salzmann is retiring, and Roivant has appointed its own president and chief operating officer, Eric Venker, to take Salzmann’s place, with the aim of giving Roivant a tighter grasp on Immunovant’s strategic direction as IMVT-1402 advances
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
